OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
June 21, 2022
Avid Bioservices has expanded its viral vector development and manufacturing facility with the addition of analytical and process development suites.
May 16, 2022
Flexible and efficient methods are needed for biopharmaceutical manufacturing.
May 03, 2022
Digital maintenance solutions can help visualize the value and key activities provided by the equipment vendor from inception to utilization.
March 03, 2022
Developers need to consider key challenges when approaching accelerated formulation strategies to ensure success.
February 22, 2022
Noema Pharma announces first patient dosed in its Phase IIb clinical trial of mGluR5 inhibitor NOE-101 in trigeminal neuralgia.
February 03, 2022
Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants.
February 01, 2022
Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.
Shifting demands from industry innovators is leading to an increased need for flexible and agile outsourcing partners offering broad and integrated models.
January 03, 2022
A new focus on speed to market creates challenges for facility design and construction.
December 17, 2021
Genezen has opened its new process development and analytical lab for viral vector production.